A study presented at the European Society for Medical Oncology Congress 2024 and published in Nature Medicine demonstrated that trastuzumab deruxtecan (Enhertu) was effective in treating patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. The DESTINY-Breast12 trial, led by Nancy Lin, MD, showed promising results with a median progression-free survival of 17.3 months and an overall survival rate of 90%. Despite some safety concerns, the study suggests that trastuzumab deruxtecan could be a preferred treatment option for patients with HER2-positive metastatic breast cancer, regardless of the presence of brain metastases. Further real-world data analysis is needed to confirm these findings.
Source link
T-DXd Effective in Some With HER2+ Breast Cancer
